SI3014267T1 - Sredstva in postopki za ugotavljanje biološke aktivnosti nevrotoksinskih polipeptidov v celicah - Google Patents
Sredstva in postopki za ugotavljanje biološke aktivnosti nevrotoksinskih polipeptidov v celicahInfo
- Publication number
- SI3014267T1 SI3014267T1 SI201430991T SI201430991T SI3014267T1 SI 3014267 T1 SI3014267 T1 SI 3014267T1 SI 201430991 T SI201430991 T SI 201430991T SI 201430991 T SI201430991 T SI 201430991T SI 3014267 T1 SI3014267 T1 SI 3014267T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cells
- determination
- methods
- biological activity
- neurotoxin polypeptides
- Prior art date
Links
- 101710138657 Neurotoxin Proteins 0.000 title 1
- 230000004071 biological effect Effects 0.000 title 1
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
- G01N2021/6441—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13174176 | 2013-06-28 | ||
| PCT/EP2014/063531 WO2014207109A1 (en) | 2013-06-28 | 2014-06-26 | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells |
| EP14733620.0A EP3014267B1 (en) | 2013-06-28 | 2014-06-26 | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3014267T1 true SI3014267T1 (sl) | 2019-01-31 |
Family
ID=48692360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201430991T SI3014267T1 (sl) | 2013-06-28 | 2014-06-26 | Sredstva in postopki za ugotavljanje biološke aktivnosti nevrotoksinskih polipeptidov v celicah |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11976110B2 (sl) |
| EP (1) | EP3014267B1 (sl) |
| JP (1) | JP6608357B2 (sl) |
| KR (1) | KR102266362B1 (sl) |
| CN (1) | CN105339790B (sl) |
| AU (1) | AU2014301116B2 (sl) |
| CA (1) | CA2913686C (sl) |
| ES (1) | ES2699432T3 (sl) |
| HR (1) | HRP20181989T1 (sl) |
| IL (1) | IL243157B (sl) |
| LT (1) | LT3014267T (sl) |
| MX (1) | MX360513B (sl) |
| PL (1) | PL3014267T3 (sl) |
| RU (1) | RU2704808C2 (sl) |
| SG (1) | SG11201510685UA (sl) |
| SI (1) | SI3014267T1 (sl) |
| TW (1) | TWI632369B (sl) |
| WO (1) | WO2014207109A1 (sl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102514666B1 (ko) | 2014-12-19 | 2023-03-27 | 메르츠 파마 게엠베하 운트 코. 카가아 | 세포에서 BoNT/E의 생물학적 활성의 결정을 위한 수단 및 방법 |
| AU2015371726B2 (en) | 2014-12-23 | 2020-10-22 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled container |
| TWI704156B (zh) * | 2015-03-04 | 2020-09-11 | 德商曼茲法瑪股份有限公司 | 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法 |
| WO2017063743A1 (en) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
| JP7579046B2 (ja) | 2016-03-02 | 2024-11-07 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | ボツリヌス毒素を含む組成物 |
| TWI737742B (zh) | 2016-06-22 | 2021-09-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用 |
| EP3290437A1 (en) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Novel recombinant clostridial neurotoxins with decreased duration of effect |
| EP3312290A1 (en) * | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| EP3312193A1 (en) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with accelerated onset of effect |
| BR112019007831A2 (pt) | 2016-10-20 | 2019-10-01 | Harvard College | ensaios in vitro e baseados em células para medição da atividade de neurotoxinas botulínicas |
| EP3333179A1 (en) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with accelarated onset of effect |
| EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
| EP3600384A1 (en) | 2017-03-24 | 2020-02-05 | Merz Pharma GmbH & Co. KGaA | Improved use of botulinum neurotoxin in the treatment of sialorrhea |
| CA3065542A1 (en) * | 2017-05-31 | 2018-12-06 | Allergan, Inc. | Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
| US20210008156A1 (en) | 2017-10-26 | 2021-01-14 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum neurotoxins with increased duration of effect |
| WO2019101308A1 (en) | 2017-11-22 | 2019-05-31 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| CN112135840B (zh) | 2018-03-13 | 2024-01-23 | 斯米维特公司 | 与破伤风神经毒素结合的单域抗体 |
| WO2020070017A1 (en) | 2018-10-02 | 2020-04-09 | Merz Pharma Gmbh & Co. Kgaa | Novel uses of botulinum neurotoxin for treating lipoedema |
| US12171717B2 (en) | 2018-10-08 | 2024-12-24 | Merz Pharma Gmbh & Co. Kgaa | Neurotoxin prefilled vial |
| EP3825689A3 (en) | 2018-11-29 | 2021-09-15 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
| IL285634B2 (en) | 2019-02-21 | 2025-06-01 | Merz Pharma Gmbh Co Kgaa | New uses of botulinum neurotoxin to treat tremor |
| US20230329996A1 (en) | 2020-06-05 | 2023-10-19 | Merz Pharma Gmbh & Co. Kgaa | High dose and low volume botulinum toxin treatment of facial wrinkles |
| CN111621525B (zh) * | 2020-06-18 | 2021-04-23 | 中赛干细胞基因工程有限公司 | Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途 |
| US20220010355A1 (en) * | 2020-07-10 | 2022-01-13 | Galderma Holding SA | Cell based method for determination of botulinum toxin potency based on western blotting |
| AU2023221507A1 (en) | 2022-02-15 | 2024-08-08 | Merz Pharma Gmbh & Co. Kgaa | Liquid botulinum toxin formulation and use thereof |
| TW202400223A (zh) | 2022-02-15 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 液體製劑及其製備方法與用途 |
| TW202400122A (zh) | 2022-02-28 | 2024-01-01 | 德商梅茲製藥有限兩合公司 | 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法 |
| TW202435908A (zh) | 2022-11-28 | 2024-09-16 | 德商梅茲製藥有限兩合公司 | 組成物及應用其之注射裝置 |
| WO2024115413A1 (en) | 2022-11-28 | 2024-06-06 | Merz Pharma Gmbh & Co. Kgaa | High concentration botulinum toxin treatment for neck rejuvenation |
| AU2023392523A1 (en) | 2022-12-15 | 2025-04-10 | Merz Pharma Gmbh & Co. Kgaa | Injectable gel comprising botulinum toxin and uses thereof |
| WO2024189148A1 (en) | 2023-03-15 | 2024-09-19 | Merz Pharma Gmbh & Co. Kgaa | A rocking shaker for treating at least one fluid sample |
| WO2024194181A1 (en) | 2023-03-20 | 2024-09-26 | Merz Therapeutics GmbH | Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient |
| TW202515602A (zh) | 2023-05-23 | 2025-04-16 | 德商梅茲治療有限公司 | 用於治療周邊神經病變性疼痛的肉毒桿菌毒素 |
| WO2025012403A1 (en) | 2023-07-12 | 2025-01-16 | Merz Pharma Gmbh & Co. Kgaa | Treatment of hyperpigmentation conditions by botulinum toxin |
| WO2025032220A1 (en) | 2023-08-10 | 2025-02-13 | Merz Pharma Gmbh & Co. Kgaa | Liquid botulinum toxin formulation and use thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
| US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
| EP1206554B2 (en) | 1999-08-25 | 2010-10-20 | Allergan, Inc. | Activatable recombinant neurotoxins |
| US7115399B2 (en) | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
| US6984375B2 (en) | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| GB2398636A (en) | 2003-02-21 | 2004-08-25 | Ipsen Ltd | Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| RU2265057C2 (ru) * | 2003-11-20 | 2005-11-27 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ индикации биоцидной активности перекисных дезинфицирующих растворов к ботулиническому нейротоксину |
| US8137924B2 (en) | 2003-12-19 | 2012-03-20 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
| MX2007000794A (es) | 2004-07-26 | 2007-04-09 | Merz Pharma Gmbh & Co Kgaa | Composicion terapeutica con una neurotoxina botulinica. |
| GB2416849A (en) | 2004-08-04 | 2006-02-08 | Ipsen Ltd | Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| EP2015065B1 (en) | 2006-04-28 | 2011-10-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method of quantifying neurotoxin |
| FI20070808A0 (fi) | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
| EP2235161A1 (en) | 2007-12-11 | 2010-10-06 | Research Development Foundation | Small molecules for neuronal differentiation of embryonic stem cells |
| WO2009098698A2 (en) | 2008-02-07 | 2009-08-13 | Shahar Cohen | Compartmental extract compositions for tissue engineering |
| US8198034B2 (en) * | 2008-03-14 | 2012-06-12 | Allergan, Inc. | Immuno-based botulinum toxin serotype A activity assays |
| US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| WO2010096746A1 (en) | 2009-02-20 | 2010-08-26 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
| CA2753679C (en) | 2009-02-27 | 2021-03-02 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
| SI2406371T1 (sl) | 2009-03-13 | 2018-10-30 | Allergan, Inc. | Celice, koristne za teste aktivnosti botulinskega toksina serotipa a na podlagi imunologije |
| BRPI1015311B1 (pt) * | 2009-04-27 | 2024-01-09 | Merz Pharma Gmbh & Co. Kgaa | Método para determinar a quantidade de polipeptídeo de neurotoxina processada em uma solução, dispositivo para determinação da quantidade de polipeptídeo de neurotoxina processada contida em uma solução e kit adaptado |
| WO2011022438A2 (en) * | 2009-08-18 | 2011-02-24 | Us Army Medical Research And Materiel Command | Cleavage sensitive antibodies and methods of use thereof |
| EP2470664A4 (en) | 2009-08-27 | 2013-01-16 | Synaptic Res Llc | NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS |
| JP5885255B2 (ja) | 2009-08-28 | 2016-03-15 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 罹患組織における遺伝的変異の同定 |
| WO2011047265A1 (en) * | 2009-10-16 | 2011-04-21 | Biosentinel, Inc. | Resonance energy transfer assay with synaptobrevin substrate moiety |
| EP2496689B1 (en) | 2009-11-04 | 2015-05-20 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
| CN102639054B (zh) | 2009-11-18 | 2015-02-18 | 梅斯制药两合股份有限公司 | 梭菌神经毒素的定量检测方法 |
| US9096886B2 (en) | 2011-03-11 | 2015-08-04 | Merz Pharma Gmbh & Co. Kgaa | Method for the determination of botulinum neurotoxin biological activity |
| EP2694644B1 (en) | 2011-03-30 | 2018-01-24 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| EP2761065B1 (en) | 2011-09-29 | 2017-12-06 | Cellsnap, LLC | Compositions and methods for toxigenicity testing |
| EP2798077A2 (en) | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
| EP2823053B1 (en) | 2012-03-07 | 2017-08-23 | Merz Pharma GmbH & Co. KGaA | Means and methods for determining neurotoxin activity based on a modified luciferase |
| US8778623B2 (en) | 2012-09-14 | 2014-07-15 | Wisconsin Alumni Research Foundation | Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin |
| BR112015011255A2 (pt) | 2012-11-21 | 2018-09-25 | Merz Pharma Gmbh & Co Kgaa | polinucleotídeo que codifica um polipeptídeo de fusão, vetor, polipeptídeo de fusão, célula hospedeira, método para determinar a atividade de neurotoxina, uso do polinucleotídeo e kit. |
| US9102901B2 (en) | 2012-12-20 | 2015-08-11 | Rohm And Haas Electronic Materials Llc | Methods and compositions for removal of metal hardmasks |
| HK1226481B (zh) | 2014-02-19 | 2017-09-29 | 莫茨药物股份两合公司 | 在體外試驗系統中用於使細胞對肉毒神經毒素的敏感性標準化和增加的神經節苷脂 |
| US10634683B2 (en) | 2014-11-21 | 2020-04-28 | Merz Pharma Gmbh & Co. Kgaa | Methods for the determination of the biological activities of neurotoxin polypeptides |
| KR102514666B1 (ko) | 2014-12-19 | 2023-03-27 | 메르츠 파마 게엠베하 운트 코. 카가아 | 세포에서 BoNT/E의 생물학적 활성의 결정을 위한 수단 및 방법 |
| TWI704156B (zh) | 2015-03-04 | 2020-09-11 | 德商曼茲法瑪股份有限公司 | 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法 |
-
2014
- 2014-06-26 SI SI201430991T patent/SI3014267T1/sl unknown
- 2014-06-26 LT LTEP14733620.0T patent/LT3014267T/lt unknown
- 2014-06-26 HR HRP20181989TT patent/HRP20181989T1/hr unknown
- 2014-06-26 MX MX2015016767A patent/MX360513B/es active IP Right Grant
- 2014-06-26 US US14/901,123 patent/US11976110B2/en active Active
- 2014-06-26 ES ES14733620T patent/ES2699432T3/es active Active
- 2014-06-26 CA CA2913686A patent/CA2913686C/en active Active
- 2014-06-26 JP JP2016522499A patent/JP6608357B2/ja active Active
- 2014-06-26 WO PCT/EP2014/063531 patent/WO2014207109A1/en active Application Filing
- 2014-06-26 EP EP14733620.0A patent/EP3014267B1/en active Active
- 2014-06-26 PL PL14733620T patent/PL3014267T3/pl unknown
- 2014-06-26 RU RU2015149695A patent/RU2704808C2/ru active
- 2014-06-26 CN CN201480036574.2A patent/CN105339790B/zh active Active
- 2014-06-26 KR KR1020157036607A patent/KR102266362B1/ko active Active
- 2014-06-26 SG SG11201510685UA patent/SG11201510685UA/en unknown
- 2014-06-26 AU AU2014301116A patent/AU2014301116B2/en active Active
- 2014-06-27 TW TW103122320A patent/TWI632369B/zh active
-
2015
- 2015-12-16 IL IL243157A patent/IL243157B/en active IP Right Grant
-
2024
- 2024-03-29 US US18/621,418 patent/US12275782B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| LT3014267T (lt) | 2018-12-10 |
| US20160202245A1 (en) | 2016-07-14 |
| SG11201510685UA (en) | 2016-01-28 |
| TWI632369B (zh) | 2018-08-11 |
| EP3014267B1 (en) | 2018-11-07 |
| US11976110B2 (en) | 2024-05-07 |
| JP2016528884A (ja) | 2016-09-23 |
| AU2014301116B2 (en) | 2019-11-14 |
| CA2913686A1 (en) | 2014-12-31 |
| MX360513B (es) | 2018-11-07 |
| IL243157B (en) | 2019-01-31 |
| PL3014267T3 (pl) | 2019-05-31 |
| US20240270833A1 (en) | 2024-08-15 |
| TW201537173A (zh) | 2015-10-01 |
| CA2913686C (en) | 2021-08-03 |
| AU2014301116A1 (en) | 2015-12-03 |
| MX2015016767A (es) | 2016-04-13 |
| KR102266362B1 (ko) | 2021-06-17 |
| CN105339790B (zh) | 2018-04-17 |
| KR20160023715A (ko) | 2016-03-03 |
| CN105339790A (zh) | 2016-02-17 |
| RU2704808C2 (ru) | 2019-10-31 |
| RU2015149695A (ru) | 2017-08-03 |
| HRP20181989T1 (hr) | 2019-01-25 |
| US12275782B2 (en) | 2025-04-15 |
| WO2014207109A1 (en) | 2014-12-31 |
| EP3014267A1 (en) | 2016-05-04 |
| ES2699432T3 (es) | 2019-02-11 |
| JP6608357B2 (ja) | 2019-11-20 |
| HK1215299A1 (zh) | 2016-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243157B (en) | Means and methods for determining the biological activity of neurotoxin polypeptides in cells | |
| IL266705B (en) | Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming | |
| EP2941643A4 (en) | Compositions and methods for detecting proteinase activity in biological systems | |
| IL251774A0 (en) | Methods and compositions for dosing in adoptive cell therapy | |
| PT3529616T (pt) | Ensaios in vitro e baseados em células para medir a atividade de neurotoxinas botulínicas | |
| ZA201505705B (en) | Phi-4 polypeptides and methods for their use | |
| HUE036147T2 (hu) | Adoptív sejtterápiában hasznos polipeptidek | |
| IL241286A0 (en) | Methods and materials for hematoendothelial differentiation of human pluripotential stem cells under defined conditions | |
| SG11201606934SA (en) | Improved reprogramming methods and cell culture platforms | |
| EP3027775A4 (en) | Dna sequencing and epigenome analysis | |
| SG11201405785WA (en) | Systems and methods for biological analysis | |
| GB201201100D0 (en) | Polypeptides and methods | |
| IL237620A0 (en) | Means and methods for determining biological activity of botulinum neurotoxin | |
| EP3072953A4 (en) | Cell culture container and container in which cell culture has been accommodated | |
| IL269252A (en) | Expression constructs and methods for expressing polypeptides in eukaryotic cells | |
| GB201315748D0 (en) | Biological methods and materials for use therein | |
| GB2523211B (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| EP2820034A4 (en) | MODIFIED ADIPONECTINPOLYPEPTIDES AND ITS USES | |
| EP2912164A4 (en) | MICRO-RNAS AND CELL PROGRAMMING | |
| ZA201602151B (en) | Therapy with cells from human placenta and hematopoietic cells | |
| GB201403522D0 (en) | Improvements in and relating to processed biological sample storage | |
| GB201300346D0 (en) | BiologIcal materials and uses thereof | |
| GB201304038D0 (en) | Treated cells and therapeutic uses | |
| GB201307762D0 (en) | Improvements in and relating to the analysis of biological material | |
| EP2841408A4 (en) | METHODS OF MAINTAINING AND IMPROVING CELL BIOLOGICAL FUNCTION AND ACTIVITY |